GlassScriptPhysician profile
Mehdi Muhammad
NPI 1346325388
$3,543.49
in general payments reported to CMS, 2019-2025
25 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $563 · 2021: $709 · 2022: $591 · 2023: $378 · 2024: $659 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $465.21 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $364.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.90 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $350.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $265.24 | 2020-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $264.03 | 2021-2025 | |
| Abbvie INC. | $243.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $170.50 | 2023-2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Evoke Pharma, INC. | $107.24 | 2021-2022 | |
| Amarin Pharma, INC. | $106.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $97.65 | 2021-2022 | |
| Genentech USA, INC. | $95.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $84.74 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $81.00 | 2020-2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $76.95 | 2019-2020 | |
| Exact Sciences Corporation | $64.84 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $63.60 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $60.26 | 2019-2021 | |
| Aprecia Pharmaceuticals, LLC | $39.81 | 2023 | Spritam |
| Viatris Specialty LLC | $23.87 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $19.46 | 2024 | Voquezna |
| Abbott Laboratories | $19.44 | 2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $16.90 | 2025 | |
| Arbor Pharmaceuticals, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehdi Muhammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.